KOSDAQBiotech & Pharma168330

Naturalendo Tech

₩2,015 0.00%2026-11-18 close
Market Cap
₩64B
Turnover
₩8,760,237
Volume
4.4K
Shares out.
31.8M
PER
—
PBR
3.0×
EPS
-₩88
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Overseas ingredient wins grow while losses persist

Naturalendo Tech is widening overseas adoption of its EstroG-100 ingredient, but it recorded operating losses in each year from 2022 to 2025, and its operating loss widened to KRW 1.56 billion in the third quarter of 2026.

  1. 1

    Revenue grew from KRW 14 billion in 2022 to KRW 22.3 billion in 2024 and was nearly flat at KRW 22.2 billion in 2025, down 0.2% year on year.

  2. 2

    The operating margin improved from -60.5% in 2022 to -14.8% in 2025, yet operating losses were recorded in each of the four years from 2022 to 2025.

  3. 3

    Third-quarter 2026 revenue fell 34.1% year on year to KRW 3.79 billion, and the KRW 1.56 billion operating loss was the largest of the last five quarters.

  4. 4

    Net profit attributable to controlling shareholders turned positive at KRW 108 million in the first quarter of 2026, but it returned to losses of KRW 312 million in the second quarter and KRW 1.77 billion in the third quarter.

  5. 5

    Overseas adoption news includes a Canadian Costco launch in April 2026, new North American product launches, and a South African rollout reported on November 13, 2026.

02

Business structure

Naturalendo Tech was founded in 2001 as a health-care materials research and development company that sells natural-product ingredients in cosmetic and health functional food forms. Its main brands are NEEDIN, a health functional food line, and NEEDLY, a cosmetics line, and a subsidiary produces microneedle patches.

In the first quarter of 2026, cosmetics accounted for 50.9% of revenue, Baeksuo (Cynanchum wilfordii) related products for 36.8%, food for 2.7%, and other OEM and rental income for 9.6%.

A different source that tallies the second quarter of 2026 splits revenue into cosmetics at 67%, natural-product drugs at 23% and other at 11%, so segment weights depend on the classification used.

The core ingredient EstroG-100 is a women's menopause-health material blended from three plant ingredients, Baeksuo, Dang-gui and Hansokdan, and it holds approvals or filings including a US FDA NDI notification, an EU Novel Food approval, a Canadian NPN and a Korean individually recognized ingredient designation.

Baeksuo related products are sold mainly to overseas customers in Canada, the United States and Southeast Asia. A May 2026 media report said Webber Naturals in Canada launched a single-ingredient formula with 514 mg of EstroG-100, and Sanofi's Qunol added two new products containing the ingredient in the United States.

At SupplySide Global 2026, held October 28 to 30 in Las Vegas, the company discussed finished-product applications and supply expansion with its North American partner CK Nutraceuticals. The company cites 48 patent applications and 31 registrations related to microneedles across Korea and about 30 other countries.

Competitively, the company stresses clinical evidence and multi-country approvals for a plant-based women's health ingredient, while its cosmetics unit has won domestic awards.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩5.8B-₩700M−11.9%
2025Q4₩5.2B-₩800M−16.0%
2026Q1₩5.7B-₩70,159,178−1.2%
2026Q2₩6.2B-₩200M−3.2%
2026Q3₩3.8B-₩1.6B−41.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩14B-₩8.4B-₩10.7B−60.5%−30.2%8.8%
2023₩18.8B-₩4.1B-₩5.6B−21.7%−18.1%20.2%
2024₩22.3B-₩3.8B-₩3.9B−16.9%−14.3%24.1%
2025₩22.2B-₩3.3B-₩3.2B−14.8%−13.4%54.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue rose from KRW 14 billion in 2022 to KRW 18.8 billion in 2023 (up 34.7% year on year) and KRW 22.3 billion in 2024 (up 18.5%), then edged down to KRW 22.2 billion in 2025 (down 0.2%). Within 2022 to 2025, 2024 was the largest year and 2022 the smallest.

Operating losses narrowed every year, from KRW 8.44 billion in 2022 to KRW 4.08 billion in 2023, KRW 3.77 billion in 2024 and KRW 3.29 billion in 2025, and the operating margin moved from -60.5% to -21.7%, -16.9% and -14.8%. The filings record losses in each of the four years from 2022 to 2025.

A November 2024 Sisaweek report said a loss streak has run since the company's 2015 operating loss, but that is a press account rather than a filed figure.

The net loss attributable to controlling shareholders shrank from KRW 10.7 billion in 2022 to KRW 5.63 billion, KRW 3.89 billion and KRW 3.22 billion in 2025, while the net loss including non-controlling interests was KRW 3.62 billion in 2025, a different figure.

Debt-to-equity rose from 8.8% in 2022 to 20.2% in 2023, 24.1% in 2024 and 54.1% in 2025, with total liabilities of KRW 12.6 billion and total equity of KRW 23.2 billion at end-2025.

Operating cash flow was negative KRW 4.54 billion in 2022, negative KRW 3.41 billion in 2023 and negative KRW 2.14 billion in 2024, then widened to negative KRW 5.66 billion in 2025.

Quarterly revenue went from KRW 5.75 billion in Q3 2025 to KRW 5.18 billion in Q4 2025 (down 9.9% quarter on quarter), KRW 5.7 billion in Q1 2026 (up 10.0%) and KRW 6.15 billion in Q2 2026 (up 7.9%), before falling to KRW 3.79 billion in Q3 2026 (down 38.4% quarter on quarter and down 34.1% year on year).

The operating loss went from KRW 684 million in Q3 2025 and KRW 831 million in Q4 2025 to KRW 70.16 million in Q1 2026, then widened to KRW 194 million in Q2 and KRW 1.56 billion in Q3 2026.

The Q1 2026 net profit attributable to controlling shareholders of KRW 108 million was a swing to profit, but Q2 2026 posted a loss of KRW 312 million and Q3 2026 a loss of KRW 1.77 billion, two straight quarters of losses.

The combined net loss attributable to controlling shareholders over the last four quarters, from Q4 2025 to Q3 2026, was KRW 2.76 billion.

05

Industry analysis

Demand from end markets is shifting toward women's health and healthy aging. In a November 2026 press release, the company said interest in women's health and Healthy Aging is rising in the global health functional food market.

A May 2026 trade report said the global wellness market is being reshaped around longevity, with hormone balance management before and after menopause emerging as a core category.

In structural terms, some analysts read the adoption of the same ingredient by global pharmaceutical brands, beyond supplement makers, as a sign that the ingredient is entering a standardization stage.

At this stage, the company is expanding overseas approvals and distribution, yet revenue was flat at KRW 22.2 billion in 2025 after KRW 22.3 billion in 2024. On competition, the company emphasizes human clinical testing and approvals in several countries.

However, Baeksuo-based ingredients have a history of market trust damage from the April 2015 fake Baeksuo controversy. Annual revenue then fell from KRW 44.5 billion in 2015 to KRW 6.5 billion in 2016, and recovered to KRW 13.9 billion in 2022, according to a Sisaweek report.

The cosmetics unit, NEEDLY, combines domestic award recognition with overseas distribution expansion. The company is classified as a small and medium-sized enterprise, and its market value and revenue scale are far smaller than those of large pharmaceutical-focused listed companies.

06

Outlook

On November 13, 2026, the company said a product containing EstroG-100 had launched in South Africa. It is a capsule containing 514 mg of the ingredient from a local company's menopause product, and the company described the launch as a foothold in African markets.

In Mexico, the company attended EXPO FAC 2026 in Mexico City on November 7 and 8, 2026, held a menopause women's health seminar, and said local regulatory approval is in progress. It plans to pursue pharmacy and other distribution channels depending on the approval outcome.

At SupplySide Global 2026, held October 28 to 30, 2026, it discussed finished-product applications and North American supply expansion with its partner. In March 2026 the company was named a K-Export Star 500 company, and in April 2026 its NEEDLY daily toner pad launched at Costco in Canada.

The timing at which overseas launches show up in reported revenue will be visible in the 2026 annual report and the 2027 quarterly reports.

Even after North American adoption reports in the first quarter of 2026, third-quarter 2026 revenue fell 34.1% year on year, so how overseas launches flow into quarterly results is the next point to watch.

In Korea, sales momentum of the NEEDIN health functional food and NEEDLY cosmetics lines is the key factor, and the cosmetics share is tallied anywhere from about 50% to 67% depending on the classification. The microneedle patch business is an area the company presents as a patent-backed growth line.

07

Valuation

PER
—
PBR
3.0×
ROE
-11.8%
EPS
-₩88
BPS
₩702
Dividend per share
₩0

The earnings-based multiple cannot be calculated because the company posted a combined net loss attributable to controlling shareholders of KRW 2.76 billion over the last four quarters, from Q4 2025 to Q3 2026.

Valuation is therefore often read through asset-based measures, and the price-to-book ratio sits in a range carrying a premium over net assets. One data platform's tally also shows the price-to-book ratio above the industry average. The dividend yield is well below the industry average.

On the balance sheet side, the rise in debt-to-equity from 8.8% in 2022 to 54.1% in 2025 is a factor to weigh when reading the premium over net assets. The improvement in operating margin from -60.5% to -14.8% points to a recovery in earnings capacity, which is a positive sign.

By contrast, the widening of the operating loss to KRW 1.56 billion in Q3 2026 runs in the opposite direction. In short, without an earnings-based multiple, how the market values the company depends on how it prices the growth of the overseas ingredient business.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Wider overseas ingredient adoption

Reports say EstroG-100 adoption by global brands continued in 2026, including a single-ingredient formula from Webber Naturals in Canada and two new products from Qunol, part of Sanofi, in the United States.

A South African launch was reported in November 2026, and the ingredient holds regulatory bases including a US FDA NDI notification and an EU Novel Food approval. Some commentators read this flow as a possible path to royalty-based revenue and wider partnerships.

Operating margin trend improving

The operating margin improved from -60.5% in 2022 to -21.7% in 2023, -16.9% in 2024 and -14.8% in 2025. The operating loss narrowed from KRW 8.44 billion in 2022 to KRW 3.29 billion in 2025. Losses shrank while revenue grew from KRW 14 billion to KRW 22.2 billion over the same period.

In the first quarter of 2026 the operating loss narrowed to KRW 70.16 million and net profit attributable to controlling shareholders turned positive at KRW 108 million.

Distribution and patent base

The company was named a K-Export Star 500 firm in March 2026, and its NEEDLY daily toner pad launched at Costco in Canada in April 2026. A subsidiary produces microneedle patches, and the NEEDLY cosmetics brand has domestic award recognition.

09

Bear factors

Persistent losses and a weak third quarter

Filed results record operating losses in each of the four years from 2022 to 2025. In the third quarter of 2026, revenue fell 34.1% year on year to KRW 3.79 billion, the operating loss reached KRW 1.56 billion, and the net loss attributable to controlling shareholders reached KRW 1.77 billion.

The combined net loss attributable to controlling shareholders over the last four quarters was KRW 2.76 billion. Quarterly revenue fell sharply despite the overseas adoption news.

Concentration in Baeksuo and past precedent

Baeksuo related products accounted for 36.8% of revenue in the first quarter of 2026. After the April 2015 fake Baeksuo controversy, annual revenue fell from KRW 44.5 billion in 2015 to KRW 6.5 billion in 2016.

Prosecutors ultimately closed the case without charges, but any renewed regulatory or quality issue around the raw material could affect the whole business.

Weaker financial structure

The debt-to-equity ratio rose from 8.8% in 2022 to 54.1% in 2025, and total liabilities at end-2025 were KRW 12.6 billion. Operating cash flow was negative KRW 5.66 billion in 2025, a wider deficit than the negative KRW 2.14 billion in 2024.

Whether borrowing growth slows and cash generation improves against total equity of KRW 23.2 billion is the next point to watch.

10

Risk factors

Trading and market risk

On April 10, 2026, the stock was designated as a caution-attention stock for one day. The triggers were a 15.74% price rise over three days and a 31.42% buying-involvement ratio from a specific account. According to the exchange, trading can be suspended at the investment warning and risk designation stages.

Regulatory and approval risk

Overseas sales depend on country-by-country ingredient approvals. Mexican local approval is in progress, and the timing of pharmacy and other distribution entry depends on its outcome. Although approvals exist in the United States, Canada and the EU, changes in national rules could affect timelines and sales.

Financial and concentration risk

Operating losses have been recorded for four straight years from 2022, and the operating loss has continued for five consecutive quarters through the third quarter of 2026. Operating cash flow was negative KRW 5.66 billion in 2025 and the debt-to-equity ratio reached 54.1%.

Baeksuo related products made up 36.8% of first-quarter 2026 revenue, so an issue with that single ingredient would have a large effect.

11

What to watch next

  1. December 31, 2026 (fiscal year-end)

    This is the close of the 2026 fiscal year. Checkpoints are whether the operating loss narrows from the KRW 1.56 billion loss in Q3 2026 and whether the South African and North American launches show up in fourth-quarter revenue.

  2. End of March 2027 (statutory filing deadline)

    This is the 2026 annual report. Annual revenue will be compared with KRW 22.2 billion in 2025, and the operating margin (-14.8% in 2025), debt-to-equity (54.1% in 2025) and operating cash flow trends will be updated.

  3. May 15, 2027 (statutory filing deadline)

    This is the first-quarter 2027 quarterly report. It will be compared with first-quarter 2026 revenue of KRW 5.7 billion, an operating loss of KRW 70.16 million and net profit attributable to controlling shareholders of KRW 108 million.

  4. Timing not set (after November 2026)

    Checkpoints are the outcome of Mexican local approval, entry into pharmacy and other channels, and whether supply talks with the North American partner turn into actual orders and revenue.

12

Overall view

Naturalendo Tech is a health-care materials company expanding overseas adoption of its Baeksuo-based EstroG-100 ingredient across North America, South Africa and Mexico. On filed figures, revenue rose from KRW 14 billion in 2022 to KRW 22.2 billion in 2025, and the operating margin improved from -60.5% to -14.8%.

However, operating losses were recorded in each year from 2022 to 2025, and in the third quarter of 2026 revenue fell to KRW 3.79 billion with an operating loss of KRW 1.56 billion.

The first quarter of 2026 turned net profit attributable to controlling shareholders positive at KRW 108 million, but losses in the second and third quarters mean the earnings path is uneven. On the financial side, the debt-to-equity ratio rose from 8.8% to 54.1%, and the operating cash outflow widened in 2025.

Because the last four quarters show a net loss, no earnings-based multiple is calculated, and on asset measures the stock trades at a premium to net assets. Strengths are global brand adoption and regulatory bases, while weaknesses are persistent losses, concentration in Baeksuo and the history of the past controversy.

The next checkpoints are the 2026 annual report at the end of March 2027 and the first-quarter 2027 report, which will show whether overseas launches translate into revenue and a smaller operating loss.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. jobkorea.co.kr
  2. alphasquare.co.kr
  3. butler.works
  4. kr.investing.com
  5. investing.com
  6. saramin.co.kr
  7. m.news.nate.com
  8. pinpointnews.co.kr
  9. sisaweek.com
  10. sisaweek.com
  11. medifonews.com
  12. go.seoul.co.kr
  13. foodtoday.or.kr
  14. m.news.nate.com
  15. news.nate.com
  16. foodtoday.or.kr
  17. topstarnews.net

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis